{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:06:33Z","timestamp":1789769193380,"version":"4.0.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s72197","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T22:37:35Z","timestamp":1414103855000},"page":"1985","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy"],"prefix":"10.2147","author":[{"given":"Ke-Hung","family":"Tsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Pang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Heng","family":"Juang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Lun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phei-Lang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IH","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=22136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:41:36Z","timestamp":1477867296000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/risk-factors-associated-with-ineligibility-of-adjuvant-cisplatin-based-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s72197","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}